WORLD HEALTH ORGANIZATION
ORGANISATION MONDIALE DE LA SANTÉ
WELTGESUNDHEITSORGANISATION Date: 26 February 2018
ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ
REGIONAL OFFICE FOR EUROPE Mr Jürgen Ojalo
BUREAU RÉGIONAL DE L’EUROPE
REGIONALBÜRO FÜR EUROPA
Chief Specialist
ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО European and International Coordination
Head office:
Department
UN City, Marmorvej 51, Ministry of Social Affairs
DK-2100 Copenhagen Ø, Denmark Gonsiori 29
Tel.: +45 45 33 70 00; Fax: +45 45 33 70 01
Email:
[email protected]
Estonia
Website: http://www.euro.who.int
Our reference: Dja/mab Your reference:
Notre référence: Votre référence:
Unser Zeichen: Ihr Zeichen:
См. наш номер: На Ваш номер:
Dear Mr Ojalo,
Annual status update (ASU) on measles and rubella elimination – 2017
The Vaccine-preventable Diseases and Immunization programme (VPI) of the WHO Regional Office
for Europe is pleased to inform you that the seventh meeting of the European Regional Verification
Commission for Measles and Rubella Elimination (RVC) will be held in June 2018, to review status
and achievements towards measles and rubella elimination in countries and in the Region. The RVC
will base its decision on the status of measles and rubella elimination in each Member State and the
Region on three consecutive reports submitted by the respective national verification committees
(NVCs).
All Member States are requested to submit their ASU on measles and rubella elimination activities for
the year 2017 with all relevant information by no later than 15 April 2018. Adhering to this deadline
is essential to ensure sufficient time for the analysis of data before the RVC meets. An ASU template
for 2017 and all additional documents, prepared and approved by the respective NVC, should be
submitted via SharePoint or by e-mail (
[email protected]) to the WHO Regional Office for Europe
(RVC Secretariat). We kindly ask you to use the credentials and instructions for using SharePoint as
previously provided.
Attached you will find a template for the 2017 ASU, modified version of the form used for 2016. To
ensure consistency, please follow the proposed format as explained in the instructions. To facilitate
your work on preparation of the ASU 2017, we developed a tool – an Excel file with pre-prepared
tables with formulas that will help you in calculating data. A few extra worksheets are developed to
facilitate analysis of data at subnational level and to allow presenting detailed molecular epidemiology
information if available, for your convenience. We recommend to submit this file together with ASU
2017.
In addition, we encourage you to submit any additional information that will assist the RVC in
determining the status of measles and rubella elimination in your country. Additional information that
does not fit in the template may be uploaded as a separate document. VPI stands ready to support you
in ensuring timely completion of the ASU.
UN City, Marmorvej 51 Tel.: +45 45 33 70 00 Email:
[email protected]
DK-2100 Copenhagen Ø Fax: +45 45 33 70 01 Website: http://www.euro.who.int
Denmark
We would like to take this opportunity to re-emphasize the importance of ensuring that data submitted
in this annual update are accurate and consistent with other national reports submitted to the Regional
Office.
We would also like to stress that all reports and additional information received from the NVCs
during the verification process will be carefully reviewed and analysed. RVC conclusions based on
this information will be publicly presented in various forms, as part of planned communication
activities to recognize Member States’ efforts and progress towards the Region’s immunization goals.
Should you have any questions regarding the provided template and uploading of documents, please
contact Dr Dragan Jankovic (
[email protected]) and Ms Malika Abdusalyamova
(
[email protected]).
We would like to stress that your efforts in documenting the absence of endemic transmission in your
country are highly appreciated and critical to achieving measles and rubella elimination in the Region.
The RVC and Secretariat are committed to providing you with any support that you may require.
Sincerely yours,
Robb Butler
Programme Manager
Vaccine-preventable Diseases
and Immunization
Copy for information to:
Ms Triin Uusberg, Head, European and International Coordination Department, Ministry of Social Affairs,
Gonsiori 29, 15027 Tallinn, Estonia
H.E. Mr Andre Pung, Ambassador, Permanent Mission of the Republic of Estonia to the United Nations Office
and other international organizations in Geneva, Chemin du Petit-Saconnex 28A, CH-1209 Genève,
Switzerland
H.E. Mr Märt Volmer, Ambassador Extraordinary and Plenipotentiary, Embassy of the Republic of Estonia,
Frederiksgade 19, 4th floor, 1265 Copenhagen K, Denmark
Ms Marge Reinap, Head of WHO Office, WHO Country Office, Estonia, Paldiski Road 81, 10617 Tallinn,
Estonia
–2–
Worksheet ASU Table
1.1.
1 1.1.1 c
1.1.1. d-f
2 1.1.4.1 a / 1.1.4.2 a
3 1.2 c
4 1.3.1 a-b
5 1.3.2 a-b
Additional tables, to help you summarizing the data:
6
7
8
Title
Progress towards measles and rubella elimination 2017
Number of measles and rubella cases in 2017
Number of measles/rubella/CRS cases, by case classification and origin of infection
Measles / Rubella outbreaks and sporadic cases in 2017 by availability of the genotype information
Number of suspected cases tested in 2017 by type of the laboratory
Measles surveillance performance indicators (standard and alternative)
Rubella surveillance performance indicators (standard and alternative)
to help you summarizing the data:
Measles all cases, by regional level, classification category and month
Rubella all cases, by regional level, classification category and month
Measles cases by genotypes and sequence variants 2016-2018
Page in original ASU 2017
Note:
(empty form)
Page 8
Page 9 Use for calculation and populate tables in ASU
Pages 9-10
Page 12
Use for calculation and populate tables in ASU
Page 15
Page 18 Use for calculation and populate tables in ASU
Use for calculation and populate tables in ASU. Please see also Annex
Page 19
1.2 for guidelines
Use for calculation and populate tables in ASU. Please see also Annex
Page 20
1.2 for guidelines
PLEASE FILL IN ALL THE GREEN HIGHLIGHTED CELLS!
1.1 Progress towards measles and rubella elimination, 2015-2017
Tab 1.1 - only 2017 Fill in here:
Number of population (as used for ASU)
1.1.1 Epidemiology of measles, rubella and CRS in 2017
Tab 1.1.1 c Number of measles and rubella cases in 2017
Total cases classified* as
Total suspected cases measles and rubella
(calculated automatically) (calculated automatically from Tab
1.1.1 d-e)
Measles 0 0
Rubella 0 0
* Total of laboratory-confirmed, epidemiologically linked and clinically compatible cases, regardless of origin (include imported).
Tab 1.1.1 d Number of measles cases, by case classification and origin of infection
Measles cases classified as Laboratory-confirmed Epidemiologically linked
Imported
Import-related
Endemic
Unknown
Total (excluding imported cases)
0 0
(calculated automatically)
Tab 1.1.1 e Number of rubella cases, by case classification and origin of infection
Rubella cases classified as Laboratory-confirmed Epidemiologically linked
Imported
Import-related
Endemic
Unknown
Total (excluding imported cases)
(calculated automatically)
0 0
Tab 1.1.1 f Number of CRS cases, by case classification and origin of infection
CRS cases classified as Laboratory-confirmed Epidemiologically linked
Imported
Import-related
Endemic
Unknown
Total (excluding imported cases)
0 0
(calculated automatically)
(calculated automatically after completing
Tab 1.1 - only 2017 tables 1.1.1 d-f)
Incidence / No of cases 2017
Measles incidence per 1 million population #DIV/0!
Rubella incidence per 1 million population #DIV/0!
Number of CRS cases 0
Remarks
Discarded
If number of your suspected cases differs from the automatically calculated, please note here:
mported).
Total
Clinically compatible
(calculated automatically)
0
0
0
0
0 0
Total
Clinically compatible
(calculated automatically)
0
0
0
0
0 0
Total
Clinically compatible
(calculated automatically)
0
0
0
0
0 0
1.1.4 Outbreaks in 2017
Tab 1.1.4.1 a Measles outbreaks and sporadic cases in 2017 by availability of the genotype information
Genotyped
Number of outbreaks/chains of
transmission
Number of cases in the
outbreaks/chains of transmission
Number of sporadic cases that are
not part of chains of transmission
Total number of cases
(calculated automatically)
Tab 1.1.4.2 a Rubella outbreaks and sporadic cases in 2017 by availability of the genotype information
Genotyped
Number of outbreaks/chains of
transmission
Number of cases in the
outbreaks/chains of transmission
Number of sporadic cases that are
not part of chains of transmission
Total number of cases
(calculated automatically)
17 by availability of the genotype information
Not genotyped Total
0
0
0
0
17 by availability of the genotype information
Not genotyped Total
0
0
0
0
1.2 Laboratory performance
Tab 1.2. c Number of suspected cases tested in 2017 by type of the laboratory
Laboratory performing the Number of suspected cases tested Number of suspected cases tested
test for measles for rubella
WHO-accredited lab(s)
Proficient labs overseen by
WHO- accredited lab
Nationally accredited labs
Other labs
Total
0 0
(calculated automatically)
ratory
Number of suspected cases tested
for CRS
0
1.3.1 Measles surveillance performance indicators
ad 1.3.1 a Standard indicators
Measles Fill in here:
Number of reports submitted by the deadline
Number of submitted reports
Number of expected reports
Number of suspected measles cases with adequate specimens
collected and tested in a proficient laboratory 0
(automatically filled in)
Number of suspected cases
(automatically filled in BUT you can decrease the number removing confirmed
epidemiologicaly linked cases or cases discarded as non-measles by
0
epidemiological linkage to a laboratory-confirmed case of another
communicable disease or epidemiological linkage to a measles IgM-negative
case)
Number of suspected measles cases investigated and discarded
0
as non-measles cases (automatically filled in)
Population
0
(automatically filled in)
Number of subnational administrative territories reporting the
rate of discarded cases at least 2 per 100 000 population per
year
Number of subnational administrative territories
Number of chains of transmission of measles for which
adequate samples have been submitted for viral detection / 0
genotyping (automatically filled in)
Number of chains of transmission identified
0
(automatically filled in)
Number of measles cases for which the origin of infection
(e.g. imported, import-related or endemic) has been identified 0
(automatically filled in)
The total number of measles cases
0
(automatically filled in)
Number of measles cases with an adequate investigation
Number of suspected measles cases
0
(automatically filled in)
ad 1.3.1 b Alternative indicators
Measles Fill in here:
Number of reports submitted within 48 hours
Number of suspected cases
0
(automatically filled in)
Number of measles cases tested negative for measles IgM
Population
0
(automatically filled in)
ors
Tab 1.3.1 a Standard indicators (automatically calculated)
Notes: Measles
Regular monthly or weekly reports, including “zero” reports to be
Timeliness of reporting (to
submitted by each surveillance reporting unit to national level. This does
not refer to lab reporting of cases. The deadline to submit data on the national level) (in %)
previous months or week to be defined by Member State.
Completeness of reporting (to
national level) (in %)
Rate of laboratory investigations
(in %)
A single clinical sample obtained at the first contact with the health-care
system at any time within 28 days after rash onset is considered
adequate for surveillance purposes.Laboratory that is WHO accredited Rate of discarded cases
and/or has an established quality assurance programme with oversight
by a WHO accredited laboratory.
Exclude from the number any suspected cases not tested by a
laboratory and Representativeness of reporting
(a) confirmed by epidemiological linkage, or
(b) discarded as non-measles by epidemiological linkage to a laboratory-
discarded cases
confirmed case of another communicable disease or epidemiological (in %)
linkage to a measles IgM-negative case
Viral detection (in %)
Origin of infection identified
(in %)
Timeliness of investigation (in %)
Measles viruses can be detected in nasal secretions, urine, serum and
whole blood, and dry blood spots up to seven days after onset of the
rash and in oral fluid for even longer .
An adequate investigation includes the collection of at least the
following essential data elements from each suspected measles case:
case identifier, age (or date of birth), date of rash onset, date of
specimen collection and vaccination status. Countries may wish to
collect other data that may be important for epidemiologic
investigation.
Tab 1.3.1 b Alternative indicators (automatically calculated)
Measles
Timeliness of notification (in %;
alternative to Timeliness and
Completeness indicator)
Rate of cases tested negative for
measles IgM (N)
tandard indicators (automatically calculated)
Value, rate or
Numerator Denominator Description
percentage
Percentage of measles routine surveillance reports submitted to the
not applicable 0 0
national level by the deadline
Percentage of measles routine surveillance reports submitted to the
not applicable 0 0
national level
Percentage of cases suspected for measles with adequate
not applicable 0 0 specimensc collected and tested in a WHO accredited or proficient
laboratory
The rate of suspected measles cases investigated and discarded as
not applicable 0 0 non-measles cases using laboratory testing in a proficient laboratory
and/or epidemiological linkage to another confirmed disease
Percentage of subnational administrative territories (e.g. at the
not applicable 0 0 province level or its administrative equivalent) reporting the rate of
discarded cases at least 2 per 100 000 population per year
Percentage of laboratory-confirmed chains of transmission of
not applicable 0 0 measles with samples adequate for viral detection collected and
tested in an accredited laboratory
Percentage of measles cases for which the origin of infection
not applicable 0 0
(e.g. imported, import-related or endemic) has been identified
Percentage of suspected measles cases with an adequate
not applicable 0 0
investigation initiated within 48 hours of notification
lternative indicators (automatically calculated)
Rate or
Numerator Denominator Description
percentage
Alternative to Timeliness and Completeness of reporting
not applicable 0 0 Percentage of measles case-based reports to surveillance system
submitted within 48 hours of the rash onset
Alternative to Rate of discarded cases
not applicable 0 0 The rate of cases of measles-like illnesses (MLI) whose specimens
tested IgM negative in a proficient laboratory
1.3.2 Rubella surveillance performance indicators
ad 1.3.2 a Standard indicators
Rubella Fill in here:
Number of reports submitted by the deadline
Number of submitted reports
Number of expected reports
Number of suspected rubella cases with adequate specimens
collected and tested in a proficient laboratory 0
(automatically filled in)
Number of suspected cases
(automatically filled in BUT you can decrease the number by removing
confirmed epidemiologically linked cases or discarded as non-rubella by
0
epidemiological linkage to a laboratory-confirmed case of another
communicable disease or epidemiological linkage to a rubella IgM-negative
case)
Number of suspected rubella cases investigated and discarded
0
as non-rubella cases (automatically filled in)
Population
0
(automatically filled in)
Number of subnational administrative territories reporting the
rate of discarded cases at least 2 per 100 000 population per
year
Number of subnational administrative territories
Number of chains of transmission of rubella for which adequate
samples have been submitted for viral detection / genotyping 0
(automatically filled in)
Number of chains of transmission identified
0
(automatically filled in)
Number of rubella cases for which the origin of infection
(e.g. imported, import-related or endemic) has been identified 0
(automatically filled in)
The total number of rubella cases
0
(automatically filled in)
Number of rubella cases with an adequate investigation
Number of suspected rubella cases
0
(automatically filled in)
ad 1.3.2 b Alternative indicators
Rubella Fill in here:
Number of reports submitted within 48 hours
Number of suspected cases
0
(automatically filled in)
Number of rubella cases tested negative for rubella IgM
Population
0
(automatically filled in)
ors
Notes:
Regular monthly or weekly reports, including “zero” reports to be submitted by each
surveillance reporting unit to national level. This does not refer to lab reporting of cases.
The deadline to submit data on the previous months or week to be defined by Member
State
A single clinical sample obtained at the first contact with the health-care system at any
time within 28 days after rash onset is considered adequate for surveillance purposes.
Laboratory that is WHO accredited and/or has an established quality assurance
programme with oversight by a WHO accredited laboratory.
Exclude from the number any suspected cases not tested by a laboratory and
(a) confirmed by epidemiological linkage, or
(b) discarded as non-rubella by epidemiological linkage to a laboratory-confirmed case of
another communicable disease or epidemiological linkage to a rubella IgM-negative case
Rubella viruses can be detected in nasal secretions, urine, serum and whole blood, and dry
blood spots up to seven days after onset of the rash and in oral fluid for even longer .
An adequate investigation includes the collection of at least the following essential data
elements from each suspected rubella case: case identifier, age (or date of birth), date of
rash onset, date of specimen collection and vaccination status. Countries may wish to
collect other data that may be important for epidemiologic investigation
Tab 1.3.2 a Standard indicators (automatically calculated)
Rubella Value, rate or percentage Numerator Denominator
Timeliness of reporting (to national level) (in %) not applicable 0 0
Completeness of reporting (to national level)
not applicable 0 0
(in %)
Rate of laboratory investigations (in %) not applicable 0 0
Rate of discarded cases not applicable 0 0
Representativeness of reporting discarded
cases not applicable 0 0
(in %)
Viral detection (in %) not applicable 0 0
Origin of infection identified
not applicable 0 0
(in %)
Timeliness of investigation (in %) not applicable 0 0
Tab 1.3.2 b Alternative indicators (automatically calculated)
Rubella Value, rate or percentage Numerator Denominator
Timeliness of notification (in %; alternative to
not applicable 0 0
Timeliness and Completeness indicator)
Rate of cases tested negative for rubella IgM
not applicable 0 0
(N)
Description
Percentage of rubella routine surveillance reports submitted to the national level by the
deadline
Percentage of rubella routine surveillance reports submitted to the national level
Percentage of cases suspected for rubella with adequate specimens collected and tested
in a WHO accredited or proficient laboratory
The rate of suspected rubella cases investigated and discarded as non-rubella cases
using laboratory testing in a proficient laboratory and/or epidemiological linkage to
another confirmed disease
Percentage of subnational administrative territories (e.g. at the province level or its
administrative equivalent) reporting the rate of discarded cases at least 2 per 100 000
population per year
Percentage of laboratory-confirmed chains of transmission of rubella with samples
adequate for viral detection collected and tested in an accredited laboratory
Percentage of rubella cases for which the origin of infection (e.g. imported, import-
related or endemic) has been identified
Percentage of suspected rubella cases with an adequate investigation initiated within 48
hours of notification
Description
Alternative to Timeliness and Completeness of reporting
Percentage of rubella case-based reports to surveillance system submitted within 48
hours of the rash onset
Alternative to Rate of discarded cases
The rate of cases of rubella-like illnesses (RLI) whose specimens tested IgM negative in a
proficient laboratory
Measles 2017 - number of cases
Jan Feb Mar
Suspected (calculated automatically) 0 0 0
Discarded
Classified as measles (calculated automatically) 0 0 0
National level Clinical
(population)
Epid-link
Lab confirmed
Outbreak cases
Sporadic cases
Suspected (calculated automatically) 0 0 0
Discarded
1st subnational Classified as (calculated automatically) 0 0 0
administrative level - Clinical
no. 1 Epid-link
(population) Lab confirmed
Outbreak cases
Sporadic cases
Suspected (calculated automatically) 0 0 0
Discarded
1st subnational Classified as measles (calculated automatically) 0 0 0
administrative level - Clinical
no. 2 Epid-link
(population) Lab confirmed
Outbreak cases
Sporadic cases
Suspected (calculated automatically) 0 0 0
Discarded
1st subnational Classified as measles (calculated automatically) 0 0 0
administrative level - Clinical
no. 3 Epid-link
(population) Lab confirmed
Outbreak cases
Sporadic cases
Suspected (calculated automatically) 0 0 0
Discarded
1st subnational Classified as measles (calculated automatically) 0 0 0
administrative level - Clinical
no. 4 Epid-link
(population) Lab confirmed
Outbreak cases
Sporadic cases
add as many as subnational administrative units of that level you have in country
national level data should be sum of subnational level data
Apr May Jun Jul Aug Sep Oct Nov Dec
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
Total
Rules
(calculated automatically)
0
0 Suspected = Discarded + Classified as
0
Classified as measles = Clinical + Epid-link +
0
0
0 Classified as measles = Outbreak cases + Sporadic cases
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Lab confirmed
Rubella 2017 - number of cases
Jan Feb Mar
Suspected (calculated automatically) 0 0 0
Discarded
Classified as rubella (calculated automatically) 0 0 0
National level Clinical
(population)
Epid-link
Lab confirmed
Outbreak cases
Sporadic cases
Suspected (calculated automatically) 0 0 0
Discarded
1st subnational Classified as rubella (calculated automatically) 0 0 0
administrative level - Clinical
no. 1 Epid-link
(population) Lab confirmed
Outbreak cases
Sporadic cases
Suspected (calculated automatically) 0 0 0
Discarded
1st subnational Classified as rubella (calculated automatically) 0 0 0
administrative level - Clinical
no. 2 Epid-link
(population) Lab confirmed
Outbreak cases
Sporadic cases
Suspected (calculated automatically) 0 0 0
Discarded
1st subnational Classified as rubella (calculated automatically) 0 0 0
administrative level - Clinical
no. 3 Epid-link
(population) Lab confirmed
Outbreak cases
Sporadic cases
Suspected (calculated automatically) 0 0 0
Discarded
1st subnational Classified as rubella (calculated automatically) 0 0 0
administrative level - Clinical
no. 4 Epid-link
(population) Lab confirmed
Outbreak cases
Sporadic cases
add as many as subnational administrative units of that level you have in country
national level data should be sum of subnational level data
Apr May Jun Jul Aug Sep Oct Nov Dec
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
Total
Rules
(calculated automatically)
0
0 Suspected = Discarded + Classified as
0
Classified as rubella = Clinical + Epid-link +
0
0
0 Classified as rubella = Outbreak cases + Sporadic cases
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Lab confirmed
Measles cases by genotypes and sequence variants 2016-2018
Genotype Sequence variant
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
National level Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
1st administrative level - Outbreak cases
no. 1 Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
1st administrative level -
no. 2
Sporadic cases
Outbreak cases
Sporadic cases
1st administrative level - Outbreak cases
no. 2 Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
1st administrative level - Outbreak cases
no. 3 Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
1st administrative level - Outbreak cases
no. 4 Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
no. 4
Sporadic cases
Outbreak cases
Sporadic cases
Outbreak cases
Sporadic cases
add as many as subnational administrative units of that level you have in country
add/remove genotype and variant data as per their detection at subnational level
national level data should be sum of subnational level data
-2018
okt.16 nov.16 dets.16 jaan.17 veebr.17 märts.17 apr.17 mai.17 juuni.17
juuli.17 aug.17 sept.17 okt.17 nov.17 dets.17 jaan.18 veebr.18 märts.18
Annual Status Update on
Measles and Rubella Elimination
(COUNTRY NAME HERE)
1
Dear NVC and national technical counterparts, dear colleagues,
We kindly ask you to follow the definitions (please see Annex 1.1) and instructions provided
in this form, and to enter numbers or text as required in each particular segment (table, text
box, other).
If you are using your own definitions and indicators, please provide an explanation and
clarification why and how these could be considered equivalent to or as an adequate
replacement for the WHO definitions and indicators.
If the NVC would like to provide additional data and information to the RVC, please submit
them as separate document(s).
This update is to be submitted to the WHO Regional Office for Europe by 15 April 2018.
Please upload an electronic version of the form and a scanned copy of the table with
signatures of all the NVC members to the RVC SharePoint:
http://workspace.who.int/sites/EURORVC
How to upload the report:
1. Make a copy of your report and any supporting documents and supplementary data in
original (Microsoft Word, Excel, etc.) format. PLEASE DO NOT CONVERT THIS FILE INTO
PDF FORMAT!
2. Login to RVC SharePoint, at “http://workspace.who.int/sites/EURORVC“, using the
password provided by the WHO Secretariat to the NVC chairperson and EPI manager.
3. Once you are in the RVC SharePoint Click on “Country Annual Status Reports”.
4. Select and click on your country folder.
5. Open the folder for year of reporting (2017).
6. Drag each file to the folder (specified area on top of your folder’s page) and it will be
copied.
7. Double-check that the files are uploaded under the Country Annual Status Reports/Your
country name – close and re-open your folder, and if names of uploaded files are not
visible repeat procedure.
Should you have any problems with access to the RVC SharePoint or in uploading the report,
please contact the WHO Secretariat by e-mail (
[email protected]).
2
The National Verification Committee (NVC) conclusion on measles and rubella elimination
status in 2017
Please provide your statement on the status of measles and rubella viruses’ circulation in your
country, based on the information provided by the national surveillance and immunization systems.
Tick one of the boxes below as deemed appropriate and provide rationale (main facts that led to the
NVC’s conclusion) in the text box below. If you have difficulties in deciding which one of the three
status definitions for measles and rubella elimination applies, please leave the boxes unchecked and
explain in the text box.
Measles
Endemic
Interrupted endemic transmission
Re-established endemic transmission
The NVC conclusion is based on the following:
(please see the guiding text below, then delete and replace it with your text addressing the
mentioned areas)
Epidemiology of measles in 2017 – number and description of cases and outbreaks (person-
time-place, seasonality, immunization status, known origin, rate of confirmation and
discarding of cases). Even it is not directly related to verification, you may include
information about measles mortality and cases of subacute sclerosing panencephalitis
(SSPE).
Measles surveillance quality in 2017 – systems quality and capacity to detect, report,
investigate and confirm/discard suspected cases all over the country for the entire year,
performance against surveillance indicators, other reliable indicators used in country to
confirm adequate surveillance quality and performance, additional activities (active case
finding, retrospective case/data analysis, addressing “silent” territories and populations),
integration with laboratory segment of surveillance for confirming cases and
genotypes/lineages (sporadic cases and outbreaks).
Molecular epidemiology of measles in 2017 – comprehensive analysis of epidemiological
and laboratory data on detected genotypes/lineages of measles viruses, and extended to
analysis of available data from the previous and following year looking for/to exclude
continuous circulation of >12 months.
Activities to increase population immunity in 2017 – routine immunization programme
coverage at national and subnational level, and especially where suboptimal programme
performance exists (e.g. age cohorts, territories and/or specific population with known low
coverage), supplemental immunization activities and coverage, additional studies and
surveys about immunity to measles and rubella (MR).
Sustainability of and commitment to activities on MR elimination in 2017 – political
commitment of decision-making structures and main players, involvement of partners,
promotion of and advocacy for elimination, sustainability of immunization programme,
political and technical regulations and guidelines developed or renewed, security of funds
3
and vaccine supply, organized activities aimed at particular groups (e.g. health care workers
to increase knowledge or general population to increase demand).
Characteristics and quality of data for 2017 – Are the data complete, available, valid,
representative, consistent? Are any additional data from other sources used to validate
existing data and ensure adequate understanding of measles epidemiology and assessment
of elimination status?
4
Rubella
Endemic
Interrupted endemic transmission
Re-established endemic transmission
The NVC conclusion is based on the following:
(please see the guiding text below, then delete and replace it with your text addressing the
mentioned areas)
Epidemiology of rubella and CRS in 2017 – number and description of cases and outbreaks
(person-time-place, seasonality, immunization status, known origin, rate of confirmation
and discarding of cases).
Rubella and CRS surveillance quality in 2017 – systems quality and capacity to detect,
report, investigate and confirm/discard suspected cases all over the country for the entire
year, performance against surveillance indicators, other reliable indicators used in country
to confirm adequate surveillance quality and performance, additional activities (active case
finding, retrospective case/data analysis, addressing “silent” territories and populations),
integration with laboratory segment of surveillance for confirming cases and
genotypes/lineages (sporadic cases and outbreaks).
Molecular epidemiology of rubella in 2017 – comprehensive analysis of epidemiological
and laboratory data on detected genotypes/lineages of measles viruses, and extended to
analysis of available data from previous and following years looking for/to exclude
continuous circulation of >12 months.
Activities to increase population immunity in 2017 – routine immunization programme
coverage at national and subnational level, and especially where suboptimal programme
performance exists (e.g. age cohorts, territories and/or specific population with known low
coverage), supplemental immunization activities and coverage, additional studies and
surveys about immunity to MR.
Sustainability of and commitment to activities on MR elimination in 2017 – political
commitment of decision-making structures and main players, involvement of partners,
promotion of and advocacy for elimination, sustainability of immunization programme,
political and technical regulations and guidelines developed or renewed, security of funds
and vaccine supply, organized activities aimed at particular groups (e.g. health care workers
to increase knowledge or general population to increase demand).
Characteristics and quality of data for 2017 – Are data complete, available, valid,
representative, consistent? Are any additional data from other sources used to validate
existing data and ensure adequate understanding of rubella (with CRS) epidemiology and
assessment of elimination status?
5
These conclusions are approved by the National Verification Committee (NVC)
Name NVC status Position Organization Contact Signature
details
(email, tel.)
1 Chairperson
2 Secretariat
person*
3 Member
4 Member
5 Member
6 Member
*Person with administrative duties, who may also be responsible for documenting, maintaining records and
overseeing logistics. This person may be from the national immunization or surveillance programme.
The RVC sent you its conclusions and recommendations from 6th RVC meeting. In the text
box below please provide the NVC and national technical counterparts’ response to any RVC
request for additional information or clarification.
Text box
6
Sections of the ASU form
Please complete sections 1-3, and use and add forms from Section 4 as needed, to report outbreaks
and supplemental immunization activities (SIA).
Please use provided Excel file to help you analyse the data and complete the ASU, and then
upload/send the Excel file to the RVC/Secretariat along with the ASU form.
Additional information to help you analyse the data and complete the forms is provided in Annex 1.
Section 1: Country measles and rubella profile for 2017
1.1 Epidemiologic analysis of measles, rubella and CRS
1.2 Laboratory performance - national framework for MR laboratory testing
1.3 Performance of measles and rubella surveillance against indicators
1.4 Population immunity to measles and rubella
Section 2: Update of general programme activities by components
Section 3: Activities of the National Verification Committee (NVC) and its Secretariat
3.1 Activities of the NVC in the year under review
3.2 The NVC Secretariat (list of national staff involved in preparation of ASU)
Section 4: Additional data on measles, rubella and CRS in 2017
4.1 Maps and epi curves with distribution of suspected and confirmed measles and rubella
cases and measles and rubella outbreaks in 2017
4.2 Form for outbreak reporting (use one form per each of the detected outbreaks)
4.3 Form for technical report on SIA
Annex 1: WHO guiding documents and examples
1.1 Definitions
1.2 Description of “Indicators and targets” for measuring performance of measles and
rubella surveillance
1.3 Sustain measles and rubella elimination after verification - Discussion points on risk for
re-establishing endemic transmission of diseases
Abbreviations
ASU Annual Status Update (form)
CRS congenital rubella syndrome
EQA external quality assurance
MCV measles-containing vaccine
MeaNS WHO Measles Nucleotide Surveillance online database (www.who-measles.org)
NVC National Verification Committee
RCV rubella-containing vaccine
RubeNS WHO Rubella Nucleotide Surveillance online database (www.who-rubella.org)
RVC Regional Verification Commission
SIA Supplemental immunization activities
7
Section 1: Country measles and rubella profile for 2017
1.1 Epidemiologic analysis of measles, rubella and CRS
Progress towards measles and rubella elimination, 2015-2017 - Incidence of measles and
rubella and total number of CRS cases in last three years
Incidence or number of
2015 2016 2017 Remarks
cases
Measles incidence
per 1 million population
Rubella incidence
per 1 million population
Number of CRS cases
Country population – number (denominator) used to calculate incidence in table above:
The numerator is the total number of measles/rubella cases including laboratory-confirmed, epidemiologically
linked and clinically compatible cases but excluding imported cases. For CRS cases please provide total
number of cases classified as CRS, excluding imported cases.
1.1.1 Epidemiology of measles, rubella and CRS in 2017
a) Measles and rubella surveillance is organized as:
Disease-specific surveillance (measles surveillance, rubella surveillance)
Rash and fever surveillance (syndrome-based)
Both types of surveillance systems are in place
Other (please describe in text box below)
Text box
b) Are specimens from ALL suspected cases routinely tested for both diseases by a laboratory?
No
Yes, for both diseases, in parallel or in sequence (if testing for one disease is negative)
Yes, but partially/for some of cases (if there are national guidelines or proposed testing
algorithm – please explain):
Text box
8
c) Number of measles and rubella cases in 2017
Total number of Total number of cases classified Number of discarded
suspected cases as measles or rubella cases
(from diseases-specific (laboratory-confirmed, (please indicate if these
and syndrome-based epidemiologically linked and are discarded for both
surveillance) clinically compatible cases) diseases)
Measles
Rubella
Value in cell “Total number of suspected cases” should be equal to the sum of values presented in “Total
number of cases classified as measles or rubella” and “Total number of discarded cases”. Include laboratory-
confirmed, epidemiologically linked and clinically compatible cases, regardless of origin (include imported).
If suspected cases are systematically investigated/tested for both diseases in your surveillance system
(syndromic-based surveillance; simultaneous or sequential testing in laboratories), cases suspected for
measles may be included in the total number of cases suspected for rubella, and conversely - cases suspected
for rubella may be included as cases suspected for measles.
d) Number of measles cases, by case classification and origin of infection
Measles Laboratory- Epidemiologically Clinically Total
confirmed (A) linked (B) compatible (C) (A+B+C)
Imported (I)
Import-related (II)
Endemic (III)
Unknown origin
(IV)
Total (excluding
imported cases)
(II + III + IV)
Note: Please use the Excel spreadsheet provided with this ASU, as it can help you in completing this table
e) Number of rubella cases, by case classification and origin of infection
Rubella Laboratory- Epidemiologically Clinically Total
confirmed (A) linked (B) compatible (C) (A+B+C)
Imported (I)
Import-related (II)
Endemic (III)
Unknown origin
(IV)
Total (excluding
imported cases)
(II + III + IV)
Note: Please use the Excel spreadsheet provided with this ASU, as it can help you in completing this table
9
f) Number of CRS cases, by case classification and origin of infection
CRS Laboratory- Epidemiologically Clinically Total
confirmed (A) linked (B) compatible (C) (A+B+C)
Imported (I)
Import-related
(II)
Endemic(III)
Unknown origin
(IV)
Total (excluding
imported cases)
(II+III+IV)
Note: Please use the Excel spreadsheet provided with this ASU, as it can help you in completing this table
1.1.2 Age and vaccination status of laboratory-confirmed, epidemiologically linked or
clinically compatible cases of measles and rubella (excluding imported cases)
a) Age and vaccination status of measles cases (excluding imported cases)
10-14 years
15-19 years
20-29 years
Unknown
5-9 years
1-4 years
Measles
< 1 year
Total
30
age
0 doses
1 dose
2 or more doses
Unknown status
Total
10
b) Age and vaccination status of rubella cases (excluding imported cases)
10-14 years
15-19 years
20-29 years
Unknown
Rubella
1-4 years
5-9 years
< 1 year
Total
30
age
0 doses
1 dose
2 or more doses
Unknown status
Total
1.1.3 List of administrative territories with measles and rubella cases
a) Total number of confirmed measles cases by month (classified as laboratory-confirmed,
epidemiologically-linked or clinically compatible), regardless of origin (including imported)
Administrative
territory and its Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Total
population size
Add as many rows as you may need for territories– one and the same type/level of administrative
organization (district, region, municipality) that provides routine diseases surveillance data in your
system.
11
b) Total number of confirmed rubella cases (classified as laboratory-confirmed, epidemiologically
linked or clinically compatible), regardless of origin (including imported)
Administrative
territory and its Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Total
population size
Add as many rows as you may need for territories– one and the same type/level of administrative
organization (district, region, municipality) that provides routine diseases surveillance data in your
system.
1.1.4 Outbreaks in 2017 and molecular epidemiology
NOTE: If genotyping data are available, please note that each outbreak or chain of
transmission should have only one genotype-variant. If more than one genotype-variant is
reported for an outbreak, this refers to more than one outbreak/chain of transmission and
should be described as two separate outbreaks/chains of transmission in the table.
Countries with comprehensive data are encouraged to use the additional Excel sheets
provided as tool for better visualization.
Please provide definition for an outbreak of measles and rubella used in your country in the text box
below:
Text box
1.1.4.1 Measles
a) Measles outbreaks and sporadic cases in 2017 by availability of the genotype information
MEASLES Genotyped Not genotyped Total
Number of outbreaks/chains of
transmission
Number of cases that are part of
outbreaks/chains of transmission
Number of sporadic cases that are
not part of outbreaks/chains of
transmission
Total number of cases
The value in the cell highlighted in orange should be the total number of cases classified as measles
and the same as the value for the Total number of cases classified as measles in table 1.1.1.c
12
b) Measles outbreaks in 2017 (list ALL outbreaks; if your country only reported sporadic measles
cases and NO outbreaks, please go directly to table d )
Outbreak ID Name of the Duration (Date Total First case by Outbreak Outbreak
affected of onset of the number of origin genotyped report form
territory first case, date cases in (Imported or (yes/no) attached to
(national, or of onset of the outbreak in not-imported) the ASU
list of affected last case; or 2017 (Yes/No)
sub-national “ongoing”)
territories)
Add as many rows as you need
c) Genotyped measles outbreaks/chains of transmission
Genotype-variant Outbreaks Total Duration Documented Are there
Name of the
(list all IDs) number (Date of importation sporadic cases
affected
of cases onset of the for first case with the same
territory
in 2017 first case (yes/no) variant that are
(national, or list and date of not part of the
of affected onset of the identified
subnational last case; or outbreak/chain
territories) “ongoing”) of
transmission?
If yes, how
many cases?
Please give
date of first
and last of
these sporadic
cases
13
SUM - Total SUM- Total SUM - Total
number of number of number of
genotyped cases in sporadic
outbreaks/chain outbreaks/chai cases with
s of ns of genotype
transmission transmission
Add as many rows as you need, or remove not used rows (e.g. only one genotype-variant detected)
d) Measles sporadic cases with different genotype-variant(s) than those reported in table c)
Please fill in this table ONLY IF
1) there were NO genotyped outbreaks at all reported in 2017 or
2) if NO outbreaks had the same genotype-variant(s).
Otherwise, please include the sporadic cases above in the last column of table c).
Genotype-variant Case ID/ EpidNo Name of subnational Date of onset Documented
territory from where it importation
was reported (yes/no)
SUM (Total number of
cases)
Add as many rows as you need, or remove not used rows (e.g. only one genotype-variant detected)
14
1.1.4.2 Rubella
a) Rubella outbreaks and sporadic cases in 2017 by availability of the genotype information
RUBELLA Genotyped Not genotyped Total
Number of outbreaks/chains of
transmission
Number of cases that are part of
outbreaks/chains of transmission
Number of sporadic cases that are
not part of outbreaks/chains of
transmission
Total number of cases
The value of the cell highlighted in orange should be the total number of cases classified as rubella
and the same as the value for the Total number of cases classified as rubella in table 1.1.1.c
b) Rubella outbreaks in 2017 (list ALL outbreaks; if your country only reported sporadic rubella
cases and NO outbreaks, please go directly to table d )
Outbreak ID Name of the Duration (Date Total First case by Outbreak Outbreak
affected of onset of the number of origin genotyped report form
territory first case and cases in (Imported or (yes/no) attached to
(national, or date of onset outbreak in not-imported) the ASU
list of affected of the last 2017 (yes/no)
sub-national case; or
territories) “ongoing”)
Add as many rows as you need
c) Genotyped rubella outbreaks
Genotype- Outbreaks Total Duration Documente Are there
Name of the
RubeNS sample (list all IDs) number (Date of d sporadic cases
affected
ID of cases onset of the importatio with the same
territory
in 2017 first case n for first variant that are
(national, or list and date of case not part of the
of affected onset of the (yes/no) identified
subnational last case; or outbreak/chain
territories) “ongoing”) of transmission?
If yes, how
many cases?
Please give date
of first and last
of these
sporadic cases
15
SUM - Total SUM- Total SUM - Total
number of number of cases number of
genotyped in sporadic
outbreaks/chains outbreaks/chains cases with
of transmission of transmission genotype
Add as many rows as you need, or remove not used rows (e.g. only one genotype-variant detected)
d) Rubella sporadic cases with different genotype-RubeNS sample ID than those reported in
table c).
Please fill in this table ONLY IF
1) there were NO genotyped outbreaks at all reported in 2017 or
2) if NO outbreaks had the same genotype-variant(s).
Otherwise, please include the sporadic cases above in the last column of table c).
Genotype- Case ID/ EpidNo Name of subnational Date of onset Documented
territory from where it importation
RubeNS sample ID
was reported (yes/no)
SUM (Total number of
cases
Add as many rows as you need, or remove not used rows (e.g. only one genotype-variant detected)
16
The RVC has noted that the collection and submission of more detailed subnational data (graphs and
maps) would facilitate the verification process. Therefore, if available (especially if already included
in the routinely collected and analysed data) and feasible, please provide outbreak maps (i.e. maps
showing the distribution of confirmed measles and rubella cases recognized as constituting one
outbreak or one chain of transmission) in Section 4.1 of the Annual Status Update 2017. Please
insert them in the form, or upload them as supplementary documents.
The RVC is asking the NVC and its secretariat to use Section 4.2 (Outbreak reporting form) to
provide outbreak data. It would be highly appreciated and useful if each imported case that was an
“index” case for an outbreak explained in detail, by giving the name of the country where the index
case was exposed and including available information on the place(s) or administrative district(s)
within your country where exposure might have occurred. If this information cannot fit into the
relevant cell of the form, it may be added in the textual description. As a reminder, imported
measles cases are cases exposed outside the country during the 7 to 18 days prior to rash onset as
supported by epidemiological and/or virological evidence, and not those who were exposed and
infected due to contact with a person in or from another administrative territory in your country.
17
1.2 Laboratory performance - national framework for measles and rubella laboratory
testing in 2017
a) Standard laboratory procedures for testing and case confirmation
Please select ONE of the following:
IgM serology is the first line of laboratory investigation; case confirmation may rely on additional
tests if needed.
Molecular detection is the first line of laboratory investigation; serology may be additionally
performed or not.
Other case confirmation procedure, please specify:
b) Testing and confirmation of cases by laboratory proficiency
Select all that apply regarding testing of measles, rubella and CRS suspected cases (more than one
may apply)
Testing conducted by WHO-accredited measles–rubella reference laboratory/laboratories.
Testing conducted by laboratories having an established quality assurance programme with
oversight by a WHO-accredited laboratory.
Testing conducted by laboratories having an established quality assurance programme and
accredited by a national body/institution. Please specify
EQA programme
Name of national accrediting body
Accreditation standard(s)
Other (please comment/describe)
c) Number of suspected cases tested in 2017 by type of the laboratory
Systematic screening studies as well as any other results of general screenings of population should
not be reported in this form (e.g. survey for rubella in pregnancy).
Laboratory performing the Number of Number of Number of
test suspected cases suspected cases suspected cases
tested for measles tested for rubella tested for CRS
WHO-accredited lab(s)
Proficient labs overseen by
WHO- accredited lab
Nationally accredited labs
Other labs
Total
18
1.3 Performance of measles and rubella surveillance against indicators
Please use the Excel spreadsheet provided with this ASU 2017 to calculate rates or percentages
required as surveillance indicators, and insert the calculated values in the tables of this section.
Please add any comments or clarifications in the “Remarks” column.
1.3.1 Measles surveillance performance indicators
a. Standard indicators
Indicator Value for indicator Numerator Denominator Remarks
Timeliness of reporting (to
national level) (in %)
Completeness of reporting (to
national level) (in %)
Rate of laboratory investigations
(in %)
Rate of discarded cases
Representativeness of reporting
discarded cases (in %)
Viral detection (in %)
Origin of infection identified
(in %)
Timeliness of investigation
(in %)
b. Alternative indicators – If the above standard indicators could be calculated using the available data,
there is no need to provide alternative indicators. If data is not available to calculate the standard
indicators, NVC should use these alternative indicators to assess the performance of measles
surveillance.
Indicator Value for indicator Numerator Denominator Remarks
Timeliness of notification (in %;
alternative to Timeliness and
Completeness indicator)
Rate of cases tested negative
for measles IgM (alternative to
Rate of Discarded Cases
indicator)
19
1.3.2 Rubella surveillance performance indicators
a. Standard indicators
Indicator Value for indicator Numerator Denominator Remarks
Timeliness of reporting (to
national level) (in %)
Completeness of reporting (to
national level) (in %)
Rate of laboratory investigations
(in %)
Rate of discarded cases
Representativeness of reporting
discarded cases (in %)
Viral detection (in %)
Origin of infection identified
(in %)
Timeliness of investigation
(in %)
b. Alternative indicators – If the above standard indicators could be calculated using the available data,
there is no need to provide alternative indicators. If data is not available to calculate the standard
indicators, NVC should use these alternative indicators to assess the performance of measles
surveillance.
Indicator Value for indicator Numerator Denominator Remarks
Timeliness of notification (in %;
alternative to Timeliness and
Completeness indicator)
Rate of cases tested negative
for rubella IgM (alternative to
Rate of Discarded Cases
indicator)
20
1.4 Population immunity to measles and rubella
1.4.1 Routine vaccination coverage of measles- and rubella-containing vaccines
a. Summary of vaccination coverage, 2015 - 2017
2015 2016 2017 Remarks
Routine vaccination
1
coverage
Measles-containing
vaccine, 1st dose
Measles-containing
vaccine, 2nd dose
Rubella-containing
vaccine, 1st dose
Rubella-containing
vaccine, 2nd dose
1
Vaccination coverage as in the official national routine immunization reports (JRF).
b. Methods used to determine the immunization coverage
Please describe the methods by which routine immunization coverage is determined, including both
numerator and denominator data. Please clearly indicate the source of population statistics.
1st dose Description Source of data Comments
Numerator
Denominator
2nd dose Description Source of data Comments
Numerator
Denominator
Example:
Numerator:
Number of children < 24 months of age that have received one dose of measles- and rubella-
containing vaccine given after 12 months of age
Denominator:
Number of children 12-23 months of age
Source of data:
Administrative reports from subnational level (annually updated)
21
1.4.2 Additional data to determine the population immunity in 2017
Note: Additional data from rapid coverage monitoring, coverage surveys or seroprevalence studies,
when available, should be included in the report. For published studies or final written reports,
references may be appended to this report.
Serological (S) or Targeted territory or Results
coverage (C) subpopulation
studies/surveys
1
2
3
Add/remove rows as needed
1.4.3 Information of administrative territories with measles/rubella-containing vaccine
routine coverage 90% in 2017
Are there any administrative territories with less than 90% coverage for either first and/or second
dose of measles and/or rubella-containing vaccine in 2017? (Please check the appropriate box)
No
Yes (Please provide list of such territories in table below)
Subnational coverage data are not collected or available
No subnational administrative levels in the country
Please list all administrative territories (for subnational level which immunization coverage data is
collected/available) where the coverage with the first and/or second dose was 90%.
Total number of subnational territories in the country in 2017:
Territories with Population size Coverage 1st dose Coverage 2nd dose
coverage less than 90% (%) (%)
1.
2.
3.
4.
5.
Add/remove rows as you need
22
1.4.4 Information about high-risk population groups in the country
Please indicate population groups with a higher than expected risk of developing/transmitting
measles and/or rubella due to insufficient level of vaccination coverage or known/possible measles
or rubella transmission in the country of origin. Consider for example population groups for which
vaccination coverage is influenced by religious beliefs or ethnicity, residence in specific geographic
or administrative areas, refugee or migrant status etc.. Include high-risk groups here even though
supplementary activities may have been implemented to improve coverage in these groups – these
activities should be reported in the text box under 1.4.5 c. Qualitative assessment of SIA. If details
about these populations are not available, please note in the last column (Remarks) that your
country is aware of the presence of these population groups.
No high-risk population groups
Description of high-risk Estimated Estimated % of total Estimated MR Remarks
population groups population size population vaccination
(please specify here) coverage
Add/remove rows as you need
1.4.5 Information on additional immunization activities in 2017
a. Actions taken to improve the level of immunization coverage in selected territories
and/or in high-risk population groups in 2017
b. Supplemental immunization activities (SIA)
Were supplementary immunization activities with measles/rubella – containing vaccine conducted in
2017 (please check the appropriate box)?
YES NO
23
If supplementary immunization activities were conducted, please summarize results in the table
below and complete the SIA Technical Report form (Section 4.3, one for each of SIA)
SIA Type of SIA Vaccine Dates Age range of Target Coverage
conducted (e.g. catch- used (M, (start-end) target group population achieved
as national up, mop-up, MR, MMR) size (%)
or follow-up)
subnational
Independent monitoring of SIAs is an objective measure of SIA quality. The SIA guidelines developed for
injectable vaccines (using measles- and rubella-containing vaccines) can be used as a reference. These are
available at http://www.who.int/immunization/diseases/measles/SIA-Field-Guide.pdf?ua=1,&ua=1
c. Qualitative assessment of SIA
According to administrative coverage and monitoring results (if done), provide qualitative
assessment of SIA that was conducted. Indicate whether there were any geographic clusters
and/or high-risk groups where SIA coverage was less than 90%.
24
Section 2: Update of activities in country towards measles and rubella
elimination
Please indicate in the table below any programmatic changes related to measles, rubella and CRS
that took place in your country in 2017. Please describe ongoing or new activities in the country in
regards to CRS surveillance.
Area of work
Strategies (considering
national and WHO
regional strategies; any
changes or new
strategies introduced)
Immunization
requirements and
schedule, routine and
supplemental
Surveillance and
reporting
CRS-specific activities
(ongoing and new)
Other
25
Section 3: Activities of the National Verification Committee (NVC) and its
Secretariat
3.1 Activities of the NVC in the year under review
Please provide a brief summary of the NVC activities conducted in the year under review (you may
extend your answer to include conducted and planned activities in the current year). Include key
issues addressed, and list any concerns that have arisen (e.g. NVC concerns about the national
programme, challenges in organizing and/or holding regular NVC meetings)
Activity Date Highlights Challenges
(Month/Year)
1
2
3
Add/remove rows as you need
3.2 The NVC Secretariat (list of national staff involved in preparation of ASU)
Name Function in Position Organization Contact details (e-
national health mail, tel.)
system*
1
2
3
4
5
* Key national public health experts who are responsible for or involved in operational aspects of immunization
programme, surveillance, measles/rubella reference laboratory and other programme areas.
26
Section 4: Additional data on measles, rubella and CRS in 2017
4.1 Maps and epi curves with distribution of suspected and confirmed measles and rubella
cases and measles and rubella outbreaks in 2017
The RVC has noted that the collection and submission of more detailed subnational data (graphs and
maps, epi curves with suspected/confirmed cases, epi curves with different genotypes) would
facilitate the verification process. Therefore, if available (especially if already included in the
routinely collected and analysed data) and feasible, please provide:
a) maps with distribution of confirmed and suspected measles and rubella cases by
subnational administrative territories, preferably at the level of districts or equivalent basic
administrative level (or any other territorial presentation of data);
b) epi curves with distribution of cases (time/place).
If it is technically challenging to insert them into this form, please upload/send them as
supplementary documents.
27
4.2 Outbreak reporting form (please fill-out one per each outbreak and add to ASU)
Measles/Rubella Aggregate Outbreak Reporting Form
(Please fill this form after each measles rub ella outb reak investigated and email to
[email protected] or Fax +45 39171863 )
Instructions to fill this form
Outbreak Identification Cases detail Lab Detail
Outbreak ID No. of suspected cases - Male No.Suspected cases with specimen
Country No. of suspected cases - Female No. Lab conf. measles cases
1st admin level No. of suspected cases - Total No. Lab conf. rubella cases
2nd admin level No. Deaths Genotype
Date of rash onset of first case No. Encephalitis
Date of rash onset last case No. Hospitalized
Outbreak Notification Date Only rubella cases: No. Pregnant Women No. WCBA
Current Outbreak Status Name and contact detail of the person reporting this outbreak Date of this report to
Outbreak end date WHO Europe
Importation (Y/N)
If yes, from which country
Epidemiological detail of confirmed cases (lab confirmed, epi linked and clinical)
Age Group 5-9 10 - 19 20 - 29 ≥ 30
< 1 year 1-4 years Unknown
Vaccination Status years years years years Total
0 dose 0
1 dose 0
2+ doses 0
Vaccination status not known 0
Vaccinated with unspecified
0
number of dose
Total 0 0 0 0 0 0 0 0
Description of outbreak
Measures taken to prevent/control further spread of outbreak
Sub-national outbreak spread detail (please provide this detail if available)
Cases
Province District Date of first cases Total reported cases comments
investigated
28
Instructions to fill in the Measles/Rubella Aggregate Outbreak Reporting Form for reporting
measles or rubella outbreaks to the WHO Regional Office for Europe
Please send the outbreak reports to the WHO Regional Office Europe or ECDC, to the same address
you send the monthly measles or rubella reports.
Please submit this form for each measles or rubella outbreak in your country. This form should be
sent as soon as an outbreak is reported by the referent national surveillance health institution (the
one in charge for outbreak response). A final report should be submitted when the outbreak is
finished (following national regulation and epidemiology of disease) and should capture the most
accurate and updated data. Additional updates can be sent by the country, however a minimum of
two reports per outbreak should be sent.
Description of the cells in the reporting form:
Outbreak Identification - 11 information cells
Outbreak ID: Outbreak ID is used to identify, trace, match and update outbreak information. The ideal
outbreak ID is MEA-CCC-YYYY-99. (CCC is the 3 character ISO3 code for the country, YYYY is year of outbreak
and 99 is a series starting from 01 to number the outbreaks sequentially)
Country: Enter the name of the country.
1st and 2nd admin level: Specify the location of the outbreak's onset. Enter the name of the first and second
administrative level in the country, according to territorial organization (e.g., 1st level region, 2nd district; 1st
level province, 2nd municipalities; 1st level oblast, 2nd rayon.)
Date of rash onset of first case: Indicate the date of rash onset for the index case.
Date of rash onset of last case - Indicate the date of rash onset for the last case notified in the outbreak.
[NOTE: This information should be indicated only in the final outbreak report.]
Outbreak Notification Date - Indicate the date when the outbreak was notified to the referent surveillance
health institution (e.g., reported by MD or health care institution) Considering differences between the
surveillance and health systems in Member States, this date should be the actual date when the planning and
performing of outbreak control measures started in the referent institution.
Current Outbreak Status - Indicate "Ongoing" or "Finished".
Outbreak end date - Indicate the date when the outbreak finished. Considering differences between the
surveillance and health systems in the Member States, as well as different health regulations, the suggestion is
to use date of the last case notification as the outbreak end date (if in the period of one maximal incubation for
the outbreak-causing disease there are no other notified cases). [NOTE: This information should be indicated
in the final outbreak report.]
Importation (Y/N) - Indicate with "Yes" or "No" whether the outbreak is imported from another country.
Measles imported case are cases exposed outside the country during the 7 to 18 days prior to rash onset as
supported by epidemiological and/or virological evidence. If the index case came from or was exposed and
infected due to contact with a person from another administrative territory in the country that is NOT an
importation. In the following cell of the form enter the name of the country where the index case was
exposed.
Cases detail - 6 information cells
No. of suspected cases (3 cells; Male, Female and Total) - indicate the number of suspected cases of
measles or rubella by gender and as a total. A suspected case is any person who is under
epidemiological, clinical and/or laboratory investigation during the outbreak; and who has clinical
symptoms meeting the case definition for measles or rubella and/or possible epidemiological link
with other suspected/confirmed case.
No. Deaths - Indicate the number of deaths caused by the outbreak-causing disease during the
outbreak.
No. Encephalitis - Indicate the number of cases diagnosed with encephalitis during the outbreak.
29
No. Hospitalized - Indicate the number of cases hospitalized due to measles or rubella during the
outbreak.
Lab Detail - 4 information cells
No. Suspected cases with specimen - Indicate the number of suspected cases from whom specimens
were collected for laboratory diagnostic procedures (detection of anti rubella or measles IgM).
According to WHO Guidelines for elimination of measles, rubella and CRS, we expect that cases from
the beginning of investigation (when cluster of cases is recognized) will be tested for both diseases
(IgM for measles and IgM for rubella). Later, when the outbreak is confirmed by IgM results, countries
with low incidence of both diseases should continue with testing of suspected cases for measles and
rubella for DDg, regardless which disease is actually the cause of the outbreak.
No. Lab conf. measles cases - Indicate the number of measles cases that are confirmed IgM positive.
No. Lab conf. rubella cases - Indicate the number of rubella cases that are confirmed IgM positive.
Genotype - Indicate the genotype of virus (with isolation or by PCR only), if performed.
Only rubella cases - 2 information cells; to fill in for a rubella outbreak investigation AND for cases that are lab-
confirmed rubella cases in measles outbreak investigation.
No. Pregnant Women - Indicate the number of suspected rubella cases in pregnant women during
the rubella outbreak OR indicate the number of confirmed rubella cases in pregnant women during
the measles outbreak.
No. WCBA - Indicate the number of suspected rubella cases in Women of Childbearing Age during the
rubella outbreak OR indicate the number of confirmed rubella cases in Women of Childbearing Age
during the measles outbreak.
Name and contact detail of the person reporting this outbreak - Enter the contact information of the person
that the WHO Regional Office can contact if there is a need for additional information.
Date of this report to WHO Europe - Indicate the date when this report was sent to the WHO Regional Office
for Europe..
Table "Epidemiological detail of confirmed cases (lab confirmed, epi linked and final clinical)"
Enter information about confirmed cases during the outbreak regarding their age and immunization status.
This information should be only for the diseases causing the outbreak and the related immunization status (for
example, not rubella lab-confirmed cases during a measles outbreak or rubella immunization status of measles
cases). The totals for rows and columns will be automatically calculated.
Description of outbreak - Indicate the main epidemiological findings: any specificity regarding characteristics
of affected institutions and communities, special populations, professional exposure, immunization status, age
of cases, dominating diagnoses for hospitalization, high number of cases with severe form of disease or other
epidemiologically important findings.
Measures taken to prevent/control further spread of outbreak - Indicate the main measures taken to
prevent/control further spread of the outbreak, the outbreak response measures (e.g., school immunization).
If it is possible, in the final closing outbreak report form indicate the risk management measures and long-term
measures that are based on the lessons learned during this outbreak.
Sub-national outbreak spread detail (please provide this detail if available) - In the case that epidemiological
and laboratory findings are able to link other measles or rubella outbreaks or clusters in other administrative
territories of the country, please enter information following the title row of the table. According to the
national regulations, these cases can be considered as clusters of the reported outbreak or as individual
outbreaks. If they are considered as separate outbreak(s), please enter this information in the “Comments”
row and fill in an additional form for that outbreak(s).
30
4.3 Technical report on implementation of supplementary immunization activities
1. Country:
2. Dates of SIAs:
3. Target provinces (if not a nationwide activity):
4. Targets and results for measles / measles-rubella vaccine by first subnational level (state / province / region)
Measles / Measles-Rubella /Measles-Mumps-Rubella Vaccine
Area Target Target No. Admin Number Survey Wastage No. Serious
Age Pop Reached Coverage (and % Coverage Rate serious AEFI
districts) (if AEFI attributed
>95% available) to SIA
coverage
Add row Delete last row
5. Targets and results for other interventions by first subnational level (state / province / region)
< intervention name >*
Area Target Age Target Pop No. Reached Admin Number (and Survey
Coverage % districts) Coverage
>95%
coverage
Add row Delete last row
*Please fill out the above table for every intervention added to the SIA
6. Number (numerator and denominator) and % of monitored sites
with more than 10% un-reached children during end-process
monitoring or if LQAS is done, number and % of rejected lots.
31
Annex 1: WHO guiding documents and examples
1.1 Definitions
Based on:
Surveillance Guidelines for Measles, Rubella and Congenital Rubella Syndrome in the WHO European Region -
Update December 2012
http://www.euro.who.int/__data/assets/pdf_file/0018/79020/e93035-2013.pdf?ua=1
and
Eliminating measles and rubella. Framework for the verification process in the WHO European Region
http://www.euro.who.int/__data/assets/pdf_file/0009/247356/Eliminating-measles-and-rubella-Framework-
for-the-verification-process-in-the-WHO-European-Region.pdf?ua=1
Disease elimination: the absence of endemic measles or rubella cases in a defined geographical area
for a period of at least 12 months, in the presence of a well-performing surveillance system.
Verification of regional elimination: Regional elimination can be declared after 36 or more months
of the absence of endemic measles or rubella in all Member States.
Disease eradication: worldwide interruption of measles or rubella transmission in the presence of a
verified, well-performing surveillance system.
Endemic transmission: continuous transmission of indigenous or imported measles or rubella virus
that persists for a period of 12 months or more in a defined geographical area.
Re-establishment of endemic transmission: a situation in which epidemiological and laboratory
evidence indicate the presence of a chain of transmission of a measles or rubella virus variant that
continues uninterrupted for a period of 12 months or more in a defined geographical area where
disease was previously eliminated.
Outbreak or chain of transmission: 2 or more measles or rubella cases which are temporarily
related and epidemiologically or virologically linked, or both.
Classification of cases:
Suspected measles case: a case with signs and symptoms consistent with measles clinical criteria:
fever and
maculopapular rash and
cough or coryza (runny nose) or conjunctivitis (red eyes).
Suspected rubella case: a case with signs and symptoms consistent with rubella clinical criteria:
maculopapular rash and
cervical, suboccipital or post-auricular adenopathy, or arthralgia/arthritis.
Note: According to “Framework for verifying elimination of measles and rubella”, Weekly
epidemiological record, No. 9, 2013, 88, 89–100
(http://www.who.int/wer/2013/wer8809.pdf?ua=1)
Suspected case of measles or rubella – A patient in whom a health-care worker suspects
measles or rubella infection, or a patient with fever and maculopapular (non-vesicular) rash
32
Laboratory-confirmed measles case: a suspected case that meets the laboratory criteria for measles
case confirmation.
Laboratory-confirmed rubella case: a suspected case that meets the laboratory criteria for rubella
surveillance case confirmation.
Epidemiologically linked measles case: a suspected case that has not been adequately tested by
laboratory and that was in contact with a laboratory-confirmed measles case 7–18 days before the
onset of rash.
Epidemiologically linked rubella case: a suspected case that has not been adequately tested by
laboratory and that was in contact with a laboratory-confirmed rubella case 12–23 days prior to
onset of the disease.
Clinically compatible measles case: a suspected case that has not been adequately tested by
laboratory and has not been epidemiologically linked to a confirmed measles case.
Clinically compatible rubella case: a suspected case that has not been adequately tested by
laboratory and has not been epidemiologically linked to a confirmed rubella case.
Endemic case: a laboratory-confirmed or epidemiologically linked case of measles or rubella
resulting from endemic transmission of measles or rubella virus.
Imported case: a case exposed outside the country during the 7-18 days (measles) or 12-23 days
(rubella) prior to rash onset as supported by epidemiological and/or virological evidence.
Import-related case: a locally-acquired measles or rubella infection occurring as part of a chain of
transmission originating in an imported case, as supported by epidemiological and/or virological
evidence. (Note: if transmission of import-related cases persists for 12 months or more, cases are no
longer considered as import-related but as endemic).
Discarded case: a suspected case that was investigated and discarded, either through negative
results of adequate laboratory testing for measles and rubella or by an epidemiological link to a
laboratory-confirmed case of another disease; in addition, IgM-positive cases in recent vaccine
recipients can be discarded if they meet all of the following criteria:
history of vaccination with relevant vaccine 7 days to 6 weeks prior to specimen collection;
onset of rash 7−14 days after vaccination;
no evidence of virus transmission revealed by active search in community;
no history of travel to areas in which the virus is known to be circulating.
Genotype: Operational taxonomic unit defined on the basis of nucleotide variation between viral
strains. Measles virus genotypes are defined on the genetic analysis of the N-450 sequence, which is
the most variable region of the measles virus genome. Rubella virus genotypes are defined on
genetic analysis of the E1- 739 sequence.
33
Named strain (measles only): Measles virus variant specifically identified in MeaNS as a
representative N-450 sequence due to its important prevalence within the database (usually
associated with widespread transmission). It allows describing viral diversity with finer resolution
within a single genotype.
Case classification algorithm for measles and rubella
34
1.2 Description of “Indicators and targets” for measuring performance of measles and
rubella surveillance
Indicator Description Target and Notes
Timeliness of Percentage of measles or rubella routine surveillance reports a submitted to the national level by Target: ≥80%
reporting (to the deadline b
national level) (T)
Example: A Number of reports submitted by the deadline T=(A*100)/B (%)
B Number of expected reports
Completeness of Percentage of measles or rubella routine surveillance reportsa submitted to the national level Target: ≥80%
reporting (to
national level) (C)
Example: E Number of submitted reports C=(E*100)/B (%)
B Number of expected reports
Rate of laboratory Percentage of cases suspected for measles or rubella with adequate specimensc collected and Target: ≥80%
investigations (L) tested in a WHO accredited or proficient laboratoryd
Note: Exclude from the denominator any suspected cases not tested by a laboratory and (a)
confirmed by epidemiological linkage, or (b) discarded as non-measles/non-rubella by
epidemiological linkage to a laboratory-confirmed case of another communicable disease or
epidemiological linkage to a measles or rubella IgM-negative case
Example: F Number of suspected measles or rubella cases with adequate specimens collected and tested in L=(F*100)/G (%)
a proficient laboratory
G Number of suspected cases
Rate of discarded The rate of suspected measles or rubella cases investigated and discarded as non-measles or non- Target: At least 2
cases (D) rubella cases using laboratory testing in a proficient laboratory and/or epidemiological linkage to discarded measles
another confirmed disease or rubella cases
per 100 000
Example: H Number of suspected measles or rubella cases investigated and discarded as non- measles D=(H*100 000)/J
or non-rubella cases
J Population
Representativeness Percentage of subnational administrative territories (e.g. at the province level or its administrative Target: ≥80%
of reporting equivalent) reporting the rate of discarded cases (D) at least 2 per 100 000 population per year
discarded cases (R)
Example: K Number of subnational administrative territories reporting the rate of discarded cases (D) at R=(K*100)/M (%)
least 2 per 100 000 population per year
M Number of subnational administrative territories
Viral detection (V) Percentage of laboratory-confirmed chains of transmission of measles or rubella with samples Target: ≥ 80%
adequate for viral detection collected and tested in an accredited laboratorye
Example: P Number of chains of transmission of measles or rubella for which adequate samples have been V=(P*100)/Q (%)
submitted for viral detection / genotyping
Q Number of chains of transmission identified
Origin of infection Percentage of measles or rubella cases for which the origin of infection (e.g. imported, import- Target: ≥ 80%
identified (O) related or endemic) has been identified
Example: W Number of measles or rubella cases for which the origin of infection (e.g. imported, import- O=(W*100)/X (%)
related or endemic) has been identified
X The total number of measles or rubella cases
Timeliness of Percentage of suspected measles or rubella cases with an adequate investigation f initiated within Target: ≥ 80%
investigation (I) 48 hours of notification
Example: Y Number of measles or rubella cases with an adequate investigation I=(Y*100)/Z (%)
Z Number of suspected measles or rubella cases, respectively
a
Regular monthly or weekly reports, including “zero” reports to be submitted by each surveillance reporting unit to national level. This does not refer to lab reporting of cases.
b
The deadline to submit data on the previous months or week to be defined by Member State
c
A single clinical sample obtained at the first contact with the health-care system at any time within 28 days after rash onset is considered adequate for surveillance purposes.
d
Llaboratory that is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory.
e
Measles and rubella viruses can be detected in nasal secretions, urine, serum and whole blood, and dry blood spots up to seven days after onset of the rash and in oral fluid for even
longer.
f
An adequate investigation includes the collection of at least the following essential data elements from each suspected measles/rubella case: case identifier, age (or date of birth), date
of rash onset, date of specimen collection and vaccination status. Countries may wish to collect other data that may be important for epidemiologic investigation
35
Alternative indicators
The following two indicators should be used by countries that are unable to report standard
indicators on timeliness of reporting and/or rate of discarded cases as described above.
Timeliness of Alternative to Timeliness and Completeness of reporting Target: ≥80%
notification (Tn)
Percentage of measles or rubella case-based reports to surveillance system submitted within 48
hours of the rash onset
A Number of reports submitted within 48 hours Tn=(A*100)/B (%)
Example: B Number of suspected cases
Target: At least 2
Rate of cases Alternative to Rate of discarded cases MLI/RLI cases tested
tested negative for negative per 100
measles or rubella The rate of cases of measles or rubella-like illnesses (MLI/RLI) whose specimens tested IgM
negative in a proficient laboratory 000 population
IgM (N) (nationwide)
A Number of measles or rubella cases tested negative for measles or rubella IgM N=(A*100 000)/B
Example: B Population
36
1.3 Sustaining measles and rubella elimination after verification - Discussion points on risk
of re-establishing endemic transmission of diseases
Countries verified by the RVC as having achieved interruption of endemic measles and rubella
transmission for a period of 36 months should assess their risks for re-establishing endemic
transmission of diseases. Recognizing that the risk of importation will exist as long as measles and
rubella viruses are present and circulating in other countries, each national public health system’s
priorities are high immunity of the population, sensitive surveillance system and established
conditions and capacities for prompt and comprehensive outbreak response.
Below is a list of possible challenges and suggestions for sustaining elimination status, developed
based on recognized and reported situations in countries. It is not a comprehensive list of all issues
and it is not intended to be used as a tool with measurable indicators or thresholds. We expect that
the National Verification Committee and national technical staff (the NVC’s Secretariat) will use it to
review whether these challenges are present in the country; whether they are recognized and being
addressed, or whether there is a plan to address them; and what role the NVC can play or is playing
in supporting the national public health system dealing with these issues, with expected technical
inputs from and involvement of the national technical advisory bodies and structures.
Immunity/susceptibility of population
National immunization programme performance in recent years and routine immunization
coverage
o Monitor rates and trends related to coverage, timelines of immunization (according to
age-specific recommendations), and potential variation in coverage per vaccine dose
(due to implementation, availability, acceptance or other reasons) with first and/or
second dose.
o Define the most affected by suboptimal coverage or downward trends (e.g. territories,
populations, minorities/ethnic groups, social-economic groups…).
o Clarify the main reasons for this situation, list ongoing and planned activities to deal with
this situation and discuss further and additional steps (benefits of intervention in policy
segment, influencing decision-makers, or addressing the public) to reach/keep coverage
at 95% or higher with both doses.
Susceptible population among adolescents and adults
o Review available data or estimate the size of the susceptible population among
adolescent and adults (not immunized or immunized with just one dose due to absence
of immunization programme, different requirements and schedule, gaps in vaccine
supply) and any supplemental immunization activity taken or planned (army service,
university entry requirements, for specific occupations or work in health and educational
system, for international travel etc.)
o Review possibility of aggregation of susceptibles or possible increased contacts among
susceptibles due to social or family relations (economic migration, education
institutions, family of susceptible adults and newborn, parents and children contacts in
kindergartens).
37
o Review internal (inside country) migration, and moving of susceptibles (countries with
historical difference in immunization programme for different territories, or with
different coverage at different subnational territories).
o Identify the proportion of adolescents and adults who are born in other countries and
who were immunized according to immunization programmes of those countries, and
review their immunization programmes (coverage may be higher or lower, immunization
and two-dose schedule introduced earlier or later than in your country).
Specific subgroups of population with low immunization coverage or that are not immunized
o Identify all such groups and the reasons for their low immunization coverage (access,
denial, refusal, poor services). Have adequate steps and strategies to address their
needs been taken, or planed?
o If needed, plan additional activities to better define these groups and the best approach
to increase their coverage.
Surveillance
High sensitivity of health care system/health care workers to measles/rubella/CRS in absence of
diseases
o Check whether health care workers (HCW) are trained and systematically reminded to
stay vigilant and suspect measles/rubella/CRS, through diseases-specific reporting, or
syndromic surveillance, or as part of programmes for surveillance and reporting of
congenital malformation. If some challenges are recognized, check whether specific
actions are conducted and planned, and if not, plan for actions to be discussed.
Adequate quality of surveillance
o Assess reliability and adequacy of diseases surveillance against global measles and
rubella surveillance indicators. If global surveillance indicators are not implementable or
are incompatible with the current health system structure and procedures, other
indicators should be considered in order to assess quality of surveillance. A high quality
surveillance is the one that have every suspected case of measles, rubella and CRS
(appearing anywhere in the country during the year) reported, investigated and confirm
or discard.
o Ensure that all segments of surveillance (clinical, epidemiological and laboratory) are
coordinated and cooperate, and that every suspected case is investigated adequately
and timely to identify details of genotype and lineages of the viruses.
Ensure that surveillance data are systematically used and analysed to detect and define
susceptible individuals and groups, and that adequate measures to immunize them are
taken/planned.
Outbreak response
Ensure that lessons learned from previous outbreaks are/will be used to improve outbreak
response.
Check that all stakeholders understand that an outbreak is an emergency and its control is a high
priority.
Check that all requirements for adequate, timely response are in place, including
38
o legislation allowing timely intervention;
o up to date technical guidelines and protocols;
o health care workers and all other critical participants in outbreak response are trained
and aware of their role and responsibility;
o sufficient resources (financial, human, vaccine, logistics) are or can quickly become
available in short period,
o prepared and trained advocacy and communication teams who have developed
materials, messages and tailored ways of communication (different for different target
populations);
o planned and prepared cooperation with partners (governmental sectors, private sector,
NGOs, donors, media).
Use outbreak analysis systematically to define susceptibles, and undertake adequate measures
to immunize them to prevent similar events in future.
39
Palun registreeri.
From: Florencia Biviano [mailto:
[email protected]]
Sent: Wednesday, February 28, 2018 11:30 AM
To: Jürgen Ojalo <
[email protected]>
Cc: Andre Pung <
[email protected]>; Marge Reinap <
[email protected]>; Märt Volmer
<
[email protected]>; Triin Uusberg <
[email protected]>
Subject: Annual status update (ASU) on measles and rubella elimination – 2017 CRM:0081670
Please see the attached correspondence sent from the World Health Organization, Regional
Office for Europe. One or more attachments may be included.
Veuillez vous référer à la correspondance ci-jointe du Bureau régional de l'Europe de
l'Organisation mondiale de la santé. Une ou plusieurs annexes peuvent être jointes.
Mit der Bitte um Kenntnisnahme der beiliegenden Korrespondenz (eine oder mehrere Anlagen),
Weltgesundheitsorganisation, Regionalbüro für Europa.
См. прикрепленные письма от Европейского регионального бюро Всемирной организации
здравоохранения (один или несколько прикрепленных файлов).